CJC-1295 + ipamorelin side effects by evidence tier: what each component's human trials recorded, what the synergistic GH pulse changes, and where the combination data stops.
The CJC-1295 + ipamorelin blend pairs a GHRH analogue with a selective ghrelin-receptor agonist in one vial. Each component has a small amount of controlled human tolerability data of its own, but the pairing does not: no published trial has given the two together, so every statement about the blend's side-effect profile is built from component data, class pharmacology and inference. This page is a research reference that keeps those evidence tiers apart. It is not advice.
The CJC-1295 + ipamorelin research overview covers the two-receptor mechanism; the component pages, CJC-1295 side effects and ipamorelin side effects, set out each trial record in detail.
| Evidence tier | CJC-1295 | Ipamorelin | The blend |
|---|---|---|---|
| Controlled human data | Two 2006 trials of the DAC form, healthy adults, weeks long | IV pharmacokinetic study (1999); IV Phase 2 in post-operative ileus (2014), up to 7 days | None |
| Form in most blends | No-DAC (modified GRF 1-29) — no human study of its own | Same molecule as trialled, different route | — |
| Reported adverse events | Injection-site reactions, flushing, headache; fluid retention and joint discomfort at higher doses | No significant adverse effects (healthy men); placebo-like profile (surgical patients) | Inferred only |
| Longest documented exposure | Weeks | Seven days | None |
CJC-1295. Teichman and colleagues (Journal of Clinical Endocrinology & Metabolism, 2006) gave healthy adults single and repeated subcutaneous doses of the DAC form. The compound was described as generally safe and well tolerated; the most common events were injection-site reactions — transient pain, swelling and induration — with transient flushing and headache, and fluid retention and joint discomfort consistent with GH elevation at the higher doses. No serious adverse reactions were reported. The limitation that matters for the blend: these trials studied the DAC form, while blends are conventionally formulated with the no-DAC form, which has no published human study.
Ipamorelin. Gobburu and colleagues (Pharmaceutical Research, 1999) reported no significant adverse effects across ascending intravenous doses in healthy men, and the Beck et al. Phase 2 trial in bowel-resection patients (2014; NCT00672074) described an adverse-event profile similar to placebo over up to seven days. Both used the intravenous route; research-market material is handled subcutaneously.
Ipamorelin's selectivity. Raun et al. (European Journal of Endocrinology, 1998) found that ipamorelin released GH without raising ACTH or cortisol, even far above its GH-releasing dose. That removes the stress-hormone and prolactin effects associated with GHRP-2 and GHRP-6 from the expected profile of the blend — a finding about which effects are absent, not a measure of safety.
The pharmacological reason for the blend is also its main safety question. GHRH and GHRP-class agonists act on separate pituitary receptors, and submaximal doses given together release more growth hormone than the sum of each alone (Bowers et al., JCEM, 1990). A larger GH pulse means a larger downstream IGF-1 signal per administration than either component produces at the same dose.
Three consequences follow, none of them measured for this blend:
Two features bound the concern without resolving it. Both components act upstream of the pituitary, so somatostatin and IGF-1 negative feedback still limit the response — the argument for a more physiological profile than injected GH. And with the no-DAC form, exposure is a discrete pulse rather than the multi-day plateau the DAC trials produced. A blend that contains the DAC form instead behaves differently: sustained GH and IGF-1 elevation that cannot be withdrawn once dosed. CJC-1295, with DAC or without explains the distinction.
Applied research and community reports with ghrelin-receptor agonists describe increased appetite, drowsiness after evening administration and mild water retention, and repeated GHRP dosing is associated with a falling GH response as the pituitary adapts. That tachyphylaxis is documented for the class, not measured for this blend in a controlled study. Community sources add injection-site welts and redness — uncontrolled, unblinded self-reports without a denominator, which cannot establish incidence, causation or severity.
A blend adds product-level variables to compound-level ones. The certificate of analysis should confirm both components by mass spectrometry, including which CJC-1295 form is present; reading a peptide certificate of analysis explains how. CJC-1295 is the less stable partner and sets the shelf life once reconstituted, so the cold-chain and shelf-life guide applies. Reactions in unregulated use can trace to impurities, endotoxin or degradation rather than either molecule.
Neither CJC-1295 nor ipamorelin has a Health Canada market authorisation or DIN, and neither is an approved drug elsewhere. The World Anti-Doping Agency prohibits GHRH analogues and growth hormone secretagogues at all times under S2 and names both compounds; the blend is prohibited for tested athletes.
Has the CJC-1295 and ipamorelin combination been tested for safety? No. No published trial has administered the two together. The blend's expected profile is inferred from separate component trials — the 2006 CJC-1295 DAC studies and the intravenous ipamorelin studies — plus the class pharmacology of GH secretagogues.
What side effects did the component trials report? The CJC-1295 DAC trials reported mainly injection-site reactions, transient flushing and headache, with fluid retention and joint discomfort at higher doses and no serious adverse reactions. The ipamorelin studies reported no significant adverse effects in healthy men and a placebo-like profile in surgical patients over up to seven days.
Does combining them change the side-effect picture? Plausibly. The combination produces a synergistic GH pulse, and GH-dependent effects such as water retention, tingling and joint discomfort are dose-related. That inference has not been tested in a controlled study.
Does the blend raise cortisol or prolactin? The ipamorelin component did not in the published work, which is why it is preferred over GHRP-2 or GHRP-6 as the GHRP partner. CJC-1295 acts at the GHRH receptor and is not associated with ACTH release in the trials. The combination itself has not been measured.
Is this medical advice? No. This page summarises published research for laboratory reference. The blend is sold as research-grade material, not for human or veterinary use, and nothing above is a safety assurance or a dosing recommendation. Health decisions belong with a qualified physician.
